The recombinant humanized anti-IL-6 receptor antibody tocilizumab, an innovative drug for the treatment of rheumatoid arthritis

Bibliography

• Myllykangas-Luosujarvi RA, Aho K, Isomaki HA. Mortality in rheumatoid arthritis. Semin Arthritis Rheum 1995;25:193-202
   PubMed Web of Science ®Google Scholar
• Alamanos Y, Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin Arthritis Rheum 2006;36:182-8
   PubMed Web of Science ®Google Scholar
• Wolfe F, Allaire S, Michaud K. The prevalence and incidence of work disability in rheumatoid arthritis, and the effect of anti-tumor necrosis factor on work disability. J Rheumatol 2007;34:2126-8
   PubMed Web of Science ®Google Scholar
• Guidelines for the management of rheumatoid arthritis 2002 update American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Arthritis Rheum 2002;46:328-46
   PubMed Web of Science ®Google Scholar
• Shankar S, Handa R. Biological agents in rheumatoid arthritis. J Postgrad Med 2004;50:293-9
   PubMed Web of Science ®Google Scholar
• Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. New Engl J Med 2004;350:2167-79
   PubMed Web of Science ®Google Scholar
• Smolen JS, Maini RN. Interleukin-6: a new therapeutic target. Arthritis Res Ther 2006;8(Suppl 2):S5
   PubMed Web of Science ®Google Scholar
• Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85
   PubMed Web of Science ®Google Scholar
• Hirano T, Matsuda T, Turner M, et al. Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol 1988;18:1797-801
   PubMed Web of Science ®Google Scholar
• Houssiau FA, Devogelaer JP, Van Damme J, et al. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 1988;31:784-8
   PubMed Web of Science ®Google Scholar
• Yamazaki K, Taga T, Hirata Y, et al. Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor. Science 1988;241:825-8
   PubMed Web of Science ®Google Scholar
• Taga T, Hibi M, Hirata Y, et al. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 1989;58:573-81
   PubMed Web of Science ®Google Scholar
• Varghese JN, Moritz RL, Lou MZ, et al. Structure of the extracellular domains of the human interleukin-6 receptor α-chain. Proc Natl Acad Sci USA 2002;99:15959-64
   PubMed Web of Science ®Google Scholar
• Hibi M, Murakami M, Saito M, et al. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 1990;63:1149-157
   PubMed Web of Science ®Google Scholar
• Murakami M, Narazaki M, Hibi M, et al. Critical cytoplasmic region of the interleukin 6 signal transducer gp130 is conserved in the cytokine receptor family. Proc Natl Acad Sci USA 1991;88:11349-53
   PubMed Web of Science ®Google Scholar
• Murakami M, Hibi M, Nakagawa N, et al. IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. Science 1993;260:1808-10
   PubMed Web of Science ®Google Scholar
• Sugita T, Furukawa O, Ueno M, et al. Enhanced expression of interleukin 6 in rat and murine arthritis models. Int J Immunopharmacol 1993;15:469-76
   PubMed Web of Science ®Google Scholar
• Iwakura Y, Saijo S, Kioka Y, et al. Autoimmunity induction by human T cell leukemia virus type 1 in transgenic mice that develop chronic inflammatory arthropathy resembling rheumatoid arthritis in humans. J Immunol 1995;155:1588-98
   PubMed Web of Science ®Google Scholar
• Alonzi T, Fattori E, Lazzaro D, et al. Interleukin 6 is required for the development of collagen-induced arthritis. J Exp Med 1998;187:461-8
   PubMed Web of Science ®Google Scholar
• Takagi N, Mihara M, Morioya Y, et al. Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. Arthritis Rheum 1998;41:2117-21
   PubMed Web of Science ®Google Scholar
• Ohshima S, Saeki Y, Mima T, et al. Interleukin 6 plays a key role in the development of antigen-induced arthritis. Proc Natl Acad Sci USA 1998;95:8222-6
   PubMed Web of Science ®Google Scholar
• Sakaguchi N, Takahashi T, Hata H, et al. Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice. Nature 2003;426:454-60
   PubMed Web of Science ®Google Scholar
• Hata T, Sakaguchi N, Yoshitomi H, et al. Distinct contribution of IL-6, TNF-α, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice. J Clin Invest 2004;114:582-8
   PubMed Web of Science ®Google Scholar
• Hirota K, Hashimoto M, Yoshitomi H, et al. T cell self-reactivity forms a cytokine milieu for spontaneous development of IL-17+Th cells that cause autoimmune arthritis. J Exp Med 2007;204(1):41-7
   PubMed Web of Science ®Google Scholar
• Guerne PA, Zuraw BL, Vaughan JH, et al. Synovium as a source of interleukin 6 in vitro Contribution to local and systemic manifestations of arthritis. J Clin Invest 1989;83:585-92
   PubMed Web of Science ®Google Scholar
• Kopf M, Baumann H, Freer G, et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 1994;368:339-44
   PubMed Web of Science ®Google Scholar
• Imazeki I, Saito H, Hasegawa M, et al. IL-6 functions in cynomolgus monkeys blocked by a humanized antibody to human IL-6 receptor. Int J Immunopharmacol 1998;20:345-57
   PubMed Web of Science ®Google Scholar
• Tamura T, Udagawa N, Takaashi N, et al. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci USA 1993;90:11924-8
   PubMed Web of Science ®Google Scholar
• Nakahara H, Song J, Sugimoto M, et al. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum 2003;48:1521-9
   PubMed Web of Science ®Google Scholar
• Nemeth E, Valore EV, Territo M, et al. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003;101:2461-3
   PubMed Web of Science ®Google Scholar
• Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004;113:1271-6
   PubMed Web of Science ®Google Scholar
• Lee P, Peng H, Galbart T, et al. Regulation of hepcidin transcription by interleukin-1 and interleukin-6. Proc Natl Acad Sci USA 2005;102:1906-10
   PubMed Web of Science ®Google Scholar
• Nemeth E, Ganz T. Regulation of iron metabolism by hepcidin. Ann Rev Nutr 2006;26:323-42
   PubMed Web of Science ®Google Scholar
• Madhok R, Cilly A, Watson J, et al. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis 1993;52:232-4
   PubMed Web of Science ®Google Scholar
• Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J 1990;265:621-36
   PubMed Web of Science ®Google Scholar
• Gauldie J, Richards C, Harnish D, et al. Interferon β/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in licer cells. Proc Natl Acad Sci USA 1987;84:7251-5
   PubMed Web of Science ®Google Scholar
• Andus T, Geiger T, Hirano T, et al. Recombinant human B cell stimulatory factor 2 (BSF-2/IFN-β2) regulates β-fibrinogen and albumin mRNA levels in Fao-9 cells. FEBS lett 1987;221:18-22
   PubMed Web of Science ®Google Scholar
• Moshage HJ, Roelofs HM, Van Pelt JF, et al. The effect of interleukin-1, interleukin-6 and its interrelationship on the synthesis of serum amyloid A and C-reactive protein in primary cultures of adults human hepatocytes. Biochem Biophys Res Commun 1988;155:112-7
   PubMed Web of Science ®Google Scholar
• Sato K, Tsuchiya, Saldanha J, et al. Reshaping a human antibody to inhibit the interleukin-6-dependent tumor cell growth. Cancer Res 1993;53:851-6
   PubMed Web of Science ®Google Scholar
• Mihara M, Nishimoto N, Ohsugi Y. The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody. Expert Opin Biol Ther 2005;5:683-90
   PubMed Web of Science ®Google Scholar
• Goto H, Shimazaki C, Tatsumi T, et al. Establishment of a novel myeloma cell line KPMM2 carrying t(3;14)(q21;q32), which proliferates specifically in response to interleukin-6 through an autocrine mechanism. Leukemia 1995;9:711-8
   PubMed Web of Science ®Google Scholar
• Mihara M, Kasutani K, Okazaki M, et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol 2005;5:1731-40
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Yoshizaki K, Maeda K, et al. Toxicity, pharmacokinetics, and dose finding study of repetitive treatment with humanized anti-interleukin 6 receptor antibody, MRA, in rheumatoid arthritis–Phase I/II clinical study. J Rheumatol 2003;30:1426-435
   PubMed Web of Science ®Google Scholar
• Choy EH, Isenberg DA, Garrood T, et al. Therapeutic benefit after blocking interleukin-6 activity in rheumatoid arthritis with an anti-interleukin-6 receptor monoclonal antibody. Arthritis Rheum 2002;46:3143-50
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Yoshizaki K, Miyasaka N, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2004;50:1761-9
   PubMed Web of Science ®Google Scholar
• Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006;54:2817-29
   PubMed Web of Science ®Google Scholar
• Ogawa J, Harigai M, Akashi T, et al. Exacerbation of chronic active Epstein-Barr virus infection in a patient with rheumatoid arthritis receiving humanised anti-interleukin-6 receptor monoclonal antibody. Ann Rheum Dis 2006;65:1667-9
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Miyasaka N, Yamamoto K, et al. Efficacy and safety of tocilizumab in monotherapy, an anti-IL-6 receptor monoclonal antibody, in patients with active rheumatoid arthritis: results from a 24-week double-blind Phase III study. Ann Rheum Dis 2006;65(Suppl II):59 OP 0020
   Web of Science ®Google Scholar
• Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of Active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X-ray reader-blinded randomized, controlled trial of tocilizumab. Ann Rheum Dis 2007;66(9):1162-7
   PubMed Web of Science ®Google Scholar
• Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008; 371:987-97
   PubMed Web of Science ®Google Scholar
• Smolen J, Beaulieu A, Rubbert-Roth A, et al. Tocilizumab, a novel monoclonal antibody targeting IL-6 signalling, significantly reduces disease activity in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66(Suppl II):87 OP 0117
   Google Scholar
• Alten R, Romos-Remus C, Rovensky J, et al. Tocilizumab, a novel monoclonal antibody targeting IL-6 signalling, significantly improves quality of life in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66(Suppl II):428 SAT 0001
   Google Scholar
• Genovese M, McKay J, Nasonov N, et al. IL-6 receptor inhibition with tocilizumab reduces disease activity in patients with rheumatoid arthritis with inadequate response to a range of DMARDs: the TOWARD study [abstract L15]. American College of Rheumatology Annual Meeting; 2007
   Google Scholar
• van Gameren MM, Willemse PH, Mulder NH, et al. Effects of recombinant human interleukin-6 in cancer patients: a Phase I–II study. Blood 1994;84:1434-41
   PubMed Web of Science ®Google Scholar
• Weber J, Yang JC, Topalian SL, et al. Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies. J Clin Oncol 1993;11:499-506
   PubMed Web of Science ®Google Scholar
• Vis M, Nurmohamed MT, Wolbink G, et al. Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. J Rheumatol 2005;32:252-5
   PubMed Web of Science ®Google Scholar
• Dursunoglu D, Evrengul H, Polat B, et al. Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relationship to inflammation. Rheumatol Int 2005;25:241-5
   PubMed Web of Science ®Google Scholar
• Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor-α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised Phase III trial. Lancet 1999;354:1932-9
   PubMed Web of Science ®Google Scholar
• Tsuru T, Terao K, Suzuki M, et al. Immune response to influenza vaccine in patients with rheumatoid arthritis under IL-6 signal blockade therapy with tocilizumab. Ann Rheum Dis 2007;66(Suppl II):39 SAT 0035
   Google Scholar
• Yoshizaki K, Matsuda T, Nishimoto N, et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 1989;74:1360-7
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Sasai M, Shima Y, et al. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 2000;95:56-61
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman's disease. Blood 2005;106:2627-32
   PubMed Web of Science ®Google Scholar
• Petty R, Southwood TR, Baum J, et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol 1998;25:1991-4
   PubMedGoogle Scholar
• Sawhney S, Woo P, Murray KJ, et al. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child 2001;85:421-6
   PubMed Web of Science ®Google Scholar
• De Benedetti F, Martini A. Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease? J Rheumatol 1998;25:203-7
   PubMed Web of Science ®Google Scholar
• Yokota S, Miyamae T, Imagawa T, et al. Therapeutic efficacy of humanized recombinant anti-IL6 receptor antibody for children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2005;52:678-93
   Google Scholar
• Iwamoto M, Nara H, Hirata D, et al. Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease. Arthritis Rheum 2002;46:3388-9
   PubMed Web of Science ®Google Scholar
• Mitsuyama K, Sata M, Tanikawa K. Significance of interleukin-6 in patients with inflammatory bowel disease. Gastroenterol Jpn 1991;26:20-8
   PubMedGoogle Scholar
• Gross V, Andus T, Caesar I, et al. Evidence for continuous stimulation of interleukin-6 production in Crohn's disease. Gastroenterology 1992;102:514-9
   PubMed Web of Science ®Google Scholar
• Hyams JS, Fitzgerald JE, Treem WR, et al. Relationship of functional and antigenic interleukin 6 to disease activity in inflammatory bowel disease. Gastroenterology 1993;104:1285-92
   PubMed Web of Science ®Google Scholar
• Atreya R, Mudter J, Finotto S, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat Med 2000;6:583-8
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Yoshizaki K, Kishimoto T, et al. IL-6 is required for the development of Th1 cell-mediated murine colitis. J Immunol 2000;164:4878-82
   PubMed Web of Science ®Google Scholar
• Ito H, Takazoe M, Fukuda Y, et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 2004;126:989-96
   PubMed Web of Science ®Google Scholar
• Ito H, Hirotani T, Yamamoto M, et al. Anti-IL-6 receptor monoclonal antibody inhibits leukocyte recruitment and promotes T-cell apoptosis in a murine model of Crohn's disease. J Gastroenterol 2002;37(Suppl 14):56-61
   PubMed Web of Science ®Google Scholar
• Hirohata S, Miyamoto T. Elevated levels of interleukin-6 in cerebrospinal fluid from patients with systemic lupus erythematosus and central nervous system involvement. Arthritis Rheum 1990;33:644-9
   PubMed Web of Science ®Google Scholar
• Gordon C, Richards N, Howie AJ, et al. Urinary IL-6: a marker for mesangial proliferative glomerulonephritis? Clin Exp Immunol 1991;86:145-9
   PubMed Web of Science ®Google Scholar
• Mihara M, Fukui H, KoishiharaY, et al. Immunologic abnormality in NZB/W F1 mice. Thymus-independent expansion of B cells responding to interleukin-6. Clin Exp Immunol 1990;82:533-7
   PubMed Web of Science ®Google Scholar
• Alarcon-Riquelme M, Moller G, Fernandez C. Age-dependent responsiveness to interleukin-6 in B lymphocytes from a systemic lupus erythematosus-prone (NZB X NZW)F1 hybrid. Clin Immunol Immunopathol 1992;62:64-9
   Google Scholar
• Linker-Israeli M, Deans RJ, Wallace DJ, et al. Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J Immunol 1991;147:117-23
   PubMed Web of Science ®Google Scholar
• Mihara M, Takagi N, Takeda Y, et al. IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice. Clin Exp Immunol 1998;112:397-402
   PubMed Web of Science ®Google Scholar
• Mihara M, Nishimoto N, Yoshizaki K, et al. Influences of anti-mouse interleukin-6 receptor antibody on immune responses in mice. Immunol Lett 2002;84:223-9
   PubMed Web of Science ®Google Scholar
• Grossman RM, Krueger J, Yourish D, et al. Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc Natl Acad Sci USA 1989;86:6367-71
   PubMed Web of Science ®Google Scholar
• Frei K, Fredrikson S, Fontana A, Link H. Interleukin-6 is elevated in plasma in multiple sclerosis. J Neuroimmunol 1991;31:147-53
   PubMed Web of Science ®Google Scholar
• Sasaki A, Yasukawa H, Shouda T, et al. CIS/SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2. J Biol Chem 2000;275:29338-47
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Kishimoto T. Update on interleukin-6. In: Lipsky PE, Smolen JS, editors, Contemporary targeted therapies in rheumatology. London, UK: Informa Healthcare; 2007. p. 149-58
   Google Scholar
• Mangan PR, Harrington LE, O'Quinn DB, et al. Transforming growth factor-âinduces development of the TH17 lineage. Nature 2006;441:231-4
   PubMed Web of Science ®Google Scholar
• Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006;441:235-8
   PubMed Web of Science ®Google Scholar
• Veldhoen M, Hocking RJ, Atkins CJ, et al. TGFâin the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006;24(2):179-89
   PubMed Web of Science ®Google Scholar
• Kimura A, Naka T, Kishimoto T. IL-6-dependent and independent pathways in the development of interleukin 17-producing T helper cells. Proc Natl Acad Sci USA 2007;104:12099-104
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Miyasaka N, Yamamoto K, et al. Long-term safety and efficacy of tocilizumab (anti-IL-6 receptor monoclonal antibody) in monotherapy in partients with rheumatoid arthritis. Ann Rheum Dis 2007;66(Suppl II):122 OP 0227
   Google Scholar
• Keffer J, Probert L, Cazlaris H, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991;10:4025-31
   PubMed Web of Science ®Google Scholar
• Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 2007;7:292-304
   PubMed Web of Science ®Google Scholar
• Mihara M, Shiina M, Nishimoto N, et al. Anti-interleukin 6 receptor antibody inhibits murine AA-amyloidosis. J Rheumatol 2004;31:1132-8
   PubMed Web of Science ®Google Scholar
• Okuda Y, Takasugi K. Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum 2006;54:2997-3000
   PubMed Web of Science ®Google Scholar
• Savolainen HA, Isomaki HA. Decrease in the number of deaths from secondary amyloidosis in patients with juvenile rheumatoid arthritis. J Pheumatol 1993;20:1201-3
   PubMed Web of Science ®Google Scholar
• Gottenberg JE, Merle-Vincent F, Bentaberry F, et al. Anti-tumor necrosis factor α therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a follow up report of tolerability and efficacy. Arthritis Rheum 2003;48:2019-24
   PubMed Web of Science ®Google Scholar
• Gillmore JD, Lovat LB, Persey MR, et al. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 2001;358:24-9
   PubMed Web of Science ®Google Scholar
• Elkayam O, Hawkins PN, Lachmann H, et al. Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. Arthritis Rheum 2002;46:2571-3
   PubMed Web of Science ®Google Scholar
• Husby G. Treatment of amyloidosis and the rheumatologist. State of the art and perspectives for the future. Scand J Rheumatol 1998;27:161-5
   PubMed Web of Science ®Google Scholar
• del Rincon ID, Williams K, Stern MP, et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001;44:2737-45
   PubMed Web of Science ®Google Scholar